| Ticker Details |
Medpace Holdings, Inc.
Medpace Holdings Inc is a clinical contract research organisation. It is engaged in providing scientifically-driven clinical research-based drug and medical device development services to the biotechnology, pharmaceutical and medical device industries.
|
| IPO Date: |
August 11, 2016 |
| Sector: |
Healthcare |
| Industry: |
Medical Diagnostics and Research |
| Market Cap: |
$14.32B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$2.89 | 1.63%
|
| Avg Daily Range (30 D): |
$8.38 | 1.78%
|
| Avg Daily Range (90 D): |
$8.64 | 1.68%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.28M |
| Avg Daily Volume (30 D): |
.24M |
| Avg Daily Volume (90 D): |
.24M |
| Trade Size |
| Avg Trade Size (Sh.): |
44 |
| Avg Trade Size (Sh.) (30 D): |
20 |
| Avg Trade Size (Sh.) (90 D): |
20 |
| Institutional Trades |
| Total Institutional Trades: |
3,197 |
| Avg Institutional Trade: |
$6.76M |
| Avg Institutional Trade (30 D): |
$21.39M |
| Avg Institutional Trade (90 D): |
$20.23M |
| Avg Institutional Trade Volume: |
.04M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$8.25M |
| Avg Closing Trade (30 D): |
$25.3M |
| Avg Closing Trade (90 D): |
$23.91M |
| Avg Closing Volume: |
41.2K |
|
|
| News |
Apr 10, 2026 @ 4:00 PM
Bronstein, Gewirtz & Grossman LLC Urges Medpace Ho...
Source: Bronstein, Gewirtz & Grossman Llc
|
Apr 9, 2026 @ 12:04 AM
MEDP Stockholder Alert: Shareholder Rights Law Fir...
Source: Robbins Llp
|
Apr 7, 2026 @ 10:50 PM
MEDP INVESTOR ALERT: Medpace Holdings Inc. Investo...
Source: Robbins Geller Rudman & Dowd Llp
|
Apr 7, 2026 @ 6:57 PM
MEDP DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ...
Source: Faruqi & Faruqi, Llp
|
Apr 7, 2026 @ 5:56 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies ...
Source: Levi & Korsinsky, Llp
|
| Financials |
| |
TTM |
Q4 2025 |
FY 2025 |
|
Basic EPS
|
$15.64
|
$4.76
|
$15.64
|
|
Diluted EPS
|
$15.28
|
$4.64
|
$15.28
|
|
Revenue
|
$2.53B
|
$708.45M
|
$2.53B
|
|
Gross Profit
|
$760.62M
|
$205.32M
|
$760.62M
|
|
Net Income / Loss
|
$451.12M
|
$135.13M
|
$451.12M
|
|
Operating Income / Loss
|
$534.94M
|
$153.27M
|
$534.94M
|
|
Cost of Revenue
|
$1.77B
|
$503.13M
|
$1.77B
|
|
Net Cash Flow
|
$-172.39M
|
$211.7M
|
$-172.39M
|
|
PE Ratio
|
32.30
|
|
|
|
|
|
